TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11080605
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy without nutritional approach
Study: 972260
Drug: 3% hexachlorophene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hexachlorophene preparation
Study: 23743482
Drug: 12-weekly LSC
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-weekly LSC videos
Study: 23743482
Drug: 12-weekly HIV
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-weekly HIV prevention messages
Study: 15006431
Drug: Pindolol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 7.5 mg
Study: 10885352
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg zinc per day as zinc sulphate, 6 days a week for 6 months)
Study: 8238640
Drug: Haloperidol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (up to 6 mg/day)
Study: 8238640
Drug: Phenelzine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (up to 90 mg/day)
Study: 3804176
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg bd
Study: 25748117
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) followed by monthly bacillus Calmette-Guérin (BCG) instillations
Study: 9669004
Drug: 0.06 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg.kg‐1 rocuronium
Study: 9659028
Drug: mivacurium 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.02 mg.kg‐1
Study: 10599663
Drug: 350-mm2 Baerveldt
Normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350-mm2 Baerveldt implant
Study: 10599663
Drug: 500-mm2 Baerveldt
Normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mm2 Baerveldt implant
Study: 3052167
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg for induction, followed by 10‐min infusion of an induction dose; maintained with continuous infusion of 0.1 mg/kg per min)
Study: 3052167
Drug: Etomidate (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (18 mg for induction, followed by 2.4 mg/min for maintenance)
Study: 31785175
Drug: Responsiveness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responsiveness to deep inhalation methacholine
Study: 31785175
Drug: Dose‐response slopes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐response slopes from deep inhalation mannitol
Study: 31785175
Drug: Dose‐response slope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐response slope from non‐deep inhalation mannitol
Study: 31397597
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (440 mg)
Study: 24019420
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (100000 IU, 6 quarterly doses)
Study: 22288155
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (600 mg once a day, i.v.)
Study: 22288155
Drug: Mexidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (300 mg once a day, i.v.)
Study: 15288411
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 150-225 mg
Study: 26537218
Drug: High PL
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PL krill oil (3 g/day)
Study: 26537218
Drug: Low PL
Normalized name: marshmallow plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low PL krill oil (1.5 g/day)
Study: 21168198
Drug: Topotecan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.25 mg/m2 daily for 5 days every 21 days (regimen I)
Study: 21168198
Drug: Topotecan 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 4.0 mg/m2/day on days 1, 8, and 15 of a 28-day cycle (regimen II)
Study: 23490397
Drug: Single-tooth implants
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tooth implants
Study: 17348888
Drug: Intraindividual comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraindividual comparison (implant vs natural tooth)
Study: 14977817
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of gefitinib combined
Study: 14977817
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 or 500 mg daily)
Study: 9134944
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d of vitamin E
Study: 9134944
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d of vitamin E
Study: 9134944
Drug: 800 mg/d
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/d of vitamin E
Study: 2979270
Drug: Omeprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (30 mg o.m.)
Study: 8439641
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.d.)
Study: 28846200
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline inhalation (HSI)
Study: 23297638
Drug: Antibiotics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics of a wide spectrum of action
Study: 20545993
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg per day for 3 months)
Study: 20545993
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg per day for 3 months)
Study: 15856233
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m(2) followed by Carboplatin AUC 7
Study: 15856233
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m(2) followed by Carboplatin AUC 6
Study: 12067917
Drug: 400 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg/kg FFR‐rFVIIa and 40 to 50 U/kg heparin
Study: 12067917
Drug: 200 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Study: 12067917
Drug: 50 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Study: 1549928
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray 200 mg
Study: 4040338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adenoidectomy and tympanostomy tubes
Study: 30636639
Drug: Macintosh Laryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macintosh Laryngoscope (ML)
Study: 24666696
Drug: SB‐705498 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐705498 (600 mg)
Study: 20453006
Drug: Functional regulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional regulator III (FR‐3) treatment
Study: 16340712
Drug: Education regarding
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education regarding back therapy and pain management combined with three consecutive days of topical heat therapy (104 degrees F or 40 degrees C for 8 hours)
Study: 16340712
Drug: Education regarding
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education regarding back therapy and pain management alone
Study: 12081835
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (1 mg x kg(‐1) x d(‐1)) from 4 to 9 mo of age
Study: 12081835
Drug: Placebo from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo from 4 to 6 mo and iron supplements from 6 to 9 mo
Study: 9873848
Drug: HIV protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV protease inhibitors
Study: 8021437
Drug: Citalopram 10-30
Normalized name: citalopram 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10-30 mg
Study: 8021437
Drug: Citalopram 20-60
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20-60 mg
Study: 8021437
Drug: Imipramine 50-150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50-150 mg
Study: 28782109
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion triggered by hb < 8 g/dl
Study: 28782109
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion triggered by hb < 9.7 g/dl
Study: 21572152
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg, 80 mg, or 120 mg daily
Study: 21572152
Drug: Febuxostat (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (any dose)
Study: 17925336
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg every day)
Study: 8097102
Drug: ebastine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebastine (20 mg)
Study: 8097102
Drug: diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (15 mg)
Study: 3746897
Drug: Biological cause
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological cause group
Study: 29559597
Drug: Ozonated water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated water bath and ozonated oil topical application once a day for 4 weeks
Study: 29559597
Drug: Naftifine hydrochloride
Normalized name: Naftifine Hydrochloride
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine hydrochloride and ketoconazole cream once a day for 4 weeks
Study: 26927237
Drug: Weekly use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly use of ibuprofen
Study: 18391640
Drug: Plasma vasoconstrictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma vasoconstrictor hormones
Study: 15798044
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to lower intraocular pressure
Study: 12213354
Drug: Sarpogrelate hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate hydrochloride (5‐HT(A2) receptor antagonist)
Study: 10626097
Drug: levodopa-benserazide dispersible
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa-benserazide dispersible formulation
Study: 21541030
Drug: High-temperature meat
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-temperature meat diet with inhibitors (cruciferous vegetables, yogurt, chlorophyllin tablets)
Study: 21541030
Drug: Inhibitor diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor diet
Study: 17474807
Drug: CP-448,187 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-448,187 (3 mg/day)
Study: 15632984
Drug: Gestalt therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestalt therapy, Rosen Body Work, and Cranio Sacral therapy (2-day course followed by 6-10 individual sessions and a 1-day follow-up course)
Study: 9522319
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, eight patches/cycle)
Study: 9522319
Drug: Cyclical transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, six patches/cycle, 3 weeks on, 1 week off)
Study: 9522319
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Continuous and Cyclical)
Study: 7957543
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ciclotropium intravenous infusion
Study: 3108355
Drug: Sulpiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (1 mg/kg im) + Placebo (2 ml saline iv)
Study: 3108355
Drug: Sulpiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (1 mg/kg im)
Study: 3108355
Drug: Sulpiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (1 mg/kg im) + TRH (200 micrograms iv)
Study: 3108355
Drug: Control standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control standard insulin tolerance test (0.1 U/kg iv)
Study: 15808245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observation without treatment)
Study: 30357823
Drug: COSF 20
Normalized name: Cosfroviximab
DrugBank: Cosfroviximab (DB17774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSF 20 mg
Study: 30357823
Drug: CTAB 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTAB 20 mg
Study: 30357823
Drug: COSF 10
Normalized name: Cosfroviximab
DrugBank: Cosfroviximab (DB17774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSF 10 mg
Study: 30357823
Drug: CTAB 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTAB 10 mg
Study: 30357823
Drug: COSF 20
Normalized name: Cosfroviximab
DrugBank: Cosfroviximab (DB17774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSF 20 mg and COSF 10 mg
Study: 27387994
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen (HDER) 60/30 mg
Study: 27387994
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.0-3.0)
Study: 20839238
Drug: Dextromethorphan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan plus ultra low-dose quinidine (DMq) at 30/10mg (DMq-30)
Study: 20839238
Drug: Dextromethorphan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan plus ultra low-dose quinidine (DMq) at 20/10mg (DMq-20)
Study: 18053310
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Study: 18053310
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Study: 12723748
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Paracetamol
Study: 8740787
Drug: CMFp (Cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFp (Cyclophosphamide, Methotrexate, 5-Fluorouracil + low-dose prednisone)
Study: 1833897
Drug: Enoximone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (2 x bolus 0.5 mg/kg, infusion 5.0 mcg/kg/min)
Study: 1833897
Drug: Dopamine (3-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (3-4.0 mcg/kg/min)
Study: 6884167
Drug: lactulose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactulose (40 g)
Study: 6884167
Drug: metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (20 mg tds)
Study: 6884167
Drug: magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulfate (0.1 g/kg body weight)
Study: 27461523
Drug: Heat-stabilized rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stabilized rice bran (30 g/day)
Study: 27461523
Drug: Cooked navy
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked navy bean powder (35 g/day)
Study: 17242078
Drug: Glycopyrrolate (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.01 mg/kg)
Study: 15065643
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + Sibutramine 1 x 10 mg/d (n=22)
Study: 15065643
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + Orlistat 3 x 120 mg/d (n=25)
Study: 15065643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Diet + Sibutramine + Orlistat (n=20)
Study: 9876861
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session treatment (SS)
Study: 9876861
Drug: Treatment-as-needed intervention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-needed intervention (TAN)
Study: 7994783
Drug: Epirubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (40 mg/40 ml saline) given within 24 h of TUR and once during the 1st week, weekly for 4 weeks and then monthly for 11 months
Study: 2689017
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream (Dermovate) with occlusion using Comfeel Coloplast dressing
Study: 2689017
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream (Dermovate) without occlusion
Study: 27912875
Drug: Chamomile (1500mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile (1500mg, 500mg capsule 3 times daily)
Study: 24462735
Drug: TDF +
Normalized name: Tenofovir disoproxil fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF + placebo (300 mg TDF)
Study: 24462735
Drug: TDF +
Normalized name: Tenofovir disoproxil fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF + emtricitabine (300 mg TDF + 200 mg emtricitabine)
Study: 21122701
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d of an insoluble fraction of partially hydrolyzed soy protein (SP)
Study: 21122701
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d total milk proteins (TMP)
Study: 16796928
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery perfusion with hypothermic washed red blood cell solution during CPB
Study: 11126231
Drug: Modified cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cognitive-behavioural treatment (M-CBT)
Study: 11126231
Drug: Standard cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioural therapy (S-CBT)
Study: 2062772
Drug: urapidil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (30 mg twice daily)
Study: 6134136
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day)
Study: 20359693
Drug: Alcohol Behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Behavioral Individual Treatment (ABIT)
Study: 20359693
Drug: Alcohol Behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Behavioral Couples Treatment (ABCT)
Study: 17957149
Drug: Subcutaneous pramlintide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pramlintide injection (5 microg/unit of insulin)
Study: 17957149
Drug: Subcutaneous pramlintide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pramlintide infusion (5 microg/unit of insulin over 120 min)
Study: 17957149
Drug: Insulin-only administration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only administration
Study: 17047667
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) 50 mg
Study: 1971034
Drug: Alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (100 mg intravenous plus heparin)
Study: 399767
Drug: Modified activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified activities of daily living (ADL) index
Study: 23433257
Drug: Chloramphenicol suspension
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol suspension (1 drop)
Study: 23433257
Drug: Chloramphenicol gel
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol gel (1 application)
Study: 23433257
Drug: Netilmicin suspension
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin suspension (1 drop)
Study: 23433257
Drug: Tobramycin suspension
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin suspension (1 drop)
Study: 23433257
Drug: Chloramphenicol suspension
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol suspension (repeated instillations every 10 min for a total of 4 drops)
Study: 23433257
Drug: Chloramphenicol gel
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol gel (repeated instillations every 10 min for a total of 4 drops)
Study: 16730318
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention, weekly sessions over 6 weeks
Study: 30185575
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (ICBT) with therapist support
Study: 30185575
Drug: Unguided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet-based cognitive behaviour therapy (ICBT)
Study: 30185575
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behaviour therapy (f2f CBT)
Study: 26961111
Drug: Total risk
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total risk management (LDL‐C <80 mg/dL, systolic BP <130 mmHg, and HbA1c <6.5%)
Study: 24976447
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 7.5 mg MTX per week (group 1)
Study: 24976447
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 15 mg MTX per week (group 2)